These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 666881)

  • 1. Effect of clofibrate on in vivo triglyceride production and clearance in genetically hyperlipemic rats.
    Simonelli C; Eaton RP
    Atherosclerosis; 1978 Mar; 29(3):269-75. PubMed ID: 666881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced triglyceride secretion: a metabolic consequence of chronic exercise.
    Simonelli C; Eaton RP
    Am J Physiol; 1978 Mar; 234(3):E221-7. PubMed ID: 629336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of treatment with clofibrate on hepatic triglyceride and lipoprotein lipase activities of post heparin plasma in male patients with hyperlipoproteinemia.
    Boberg J; Boberg M; Gross R; Grundy S; Augustin J; Brown V
    Atherosclerosis; 1977 Aug; 27(4):499-503. PubMed ID: 884004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clofibrate increases lipoprotein-lipase activity in adipose tissue of hypertriglyceridaemic patients.
    Taylor KG; Holdsworth G; Galton DJ
    Lancet; 1977 Nov; 2(8048):1106-7. PubMed ID: 73012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man.
    Kesäniemi YA; Grundy SM
    JAMA; 1984 May; 251(17):2241-6. PubMed ID: 6368883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of altered thyroid status on lipid metabolism in the genetic hyperlipemic Zucker rat.
    Engelken SF; Eaton RP
    Atherosclerosis; 1981; 38(1-2):177-88. PubMed ID: 7008806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Splanchnic metabolism of free fatty acids and production of triglycerides of very low density lipoproteins in normotriglyceridemic and hypertriglyceridemic humans.
    Havel RJ; Kane JP; Balasse EO; Segel N; Basso LV
    J Clin Invest; 1970 Nov; 49(11):2017-35. PubMed ID: 5475985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Triglyceride synthesis and oleic acid catabolism by hepatic microsomes and mitochondria in clofibrate or procetofen-treated rats].
    Clouet E; Paris R
    Reprod Nutr Dev (1980); 1980; 20(3A):637-45. PubMed ID: 7349434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of clofibrate on myocardial triglyceride accumulation in female obese Zucker rats].
    Yang BX; Li Y; Liao R; Tian Q
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Nov; 39(6):962-4. PubMed ID: 19253836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypolipemic glucagon activity in isolated liver of genetic or acquired hypertriglyceridemic rats.
    Nosadini R; Meneghel A; Del Prato S; Fedele D; Tiengo A
    Diabete Metab; 1980 Jun; 6(2):129-33. PubMed ID: 7409295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous glucagon regulation in genetically hyperlipemic obese rats.
    Eaton RP; Conway M; Schade DS
    Am J Physiol; 1976 May; 230(5):1336-41. PubMed ID: 1275076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of hypocholesterolemic activity for cyclic analogs of clofibrate in normolipemic rats.
    Goldberg AP; Mellon WS; Witiak DT; Feller DR
    Atherosclerosis; 1977 May; 27(1):15-25. PubMed ID: 857813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats.
    Petit D; Bonnefis MT; Rey C; Infante R
    Atherosclerosis; 1988 Dec; 74(3):215-25. PubMed ID: 3240333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Halofenate and clofibrate: mechanism of hypotriglyceridemic action in the rat.
    Cenedella RJ; Crouthamel WG
    J Lipid Res; 1976 Mar; 17(2):156-66. PubMed ID: 1270931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lipid-lowering effect of a combination of clofibrate and DL-alpha-tocopherol nicotinate in unselected hyperlipemic patients].
    Gniwotta E; Herter B
    ZFA (Stuttgart); 1977 Apr; 53(10):565-8. PubMed ID: 324162
    [No Abstract]   [Full Text] [Related]  

  • 16. Metabolic disorders associated with hyperlipemia: activity of an extremely potent hypolipemic agent (LR 19731).
    Fregnan GB; Frigerio L; Porta R
    Pharmacology; 1981; 22(5):311-21. PubMed ID: 7255538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hyperlipemic conditions: results of their treatment with clofibrate-methandrostenolone].
    Ciammaichella A; Torcia L
    Boll Soc Ital Cardiol; 1971; 16(12):841-51. PubMed ID: 5150179
    [No Abstract]   [Full Text] [Related]  

  • 18. [Comparative studies on the cholesterol and triglyceride-lowering effect of alpha-methylthyroxine (Skleronorm) and clofibrate (Regelan) in hyperlipoproteinemias of type IIa/b and IV].
    Jantke J; Schwartzkopff W; Zschiedrich M
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():392-5. PubMed ID: 206057
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clofibrate treatment of hyperlipoproteinemia].
    Oikawa S; Midorikawa H
    Nihon Rinsho; 1994 Dec; 52(12):3285-91. PubMed ID: 7853724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clofibrate and related compounds in hyperlipoproteinaemia. A review.
    Gustafson A
    Postgrad Med J; 1975; 51(8):66-71. PubMed ID: 768950
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.